EcoDrugPlus

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSCAFG00020020525
Gene Symbol: EZH2
3 Cross references
235 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSCAFG00020023672
Gene Symbol: EGFR
3 Cross references
287 Possible Orthologues:

Epoxide Hydrolase 2

Ensembl ID : ENSCAFG00020012494
Gene Symbol: EPHX2
3 Cross references
204 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSCAFG00020019353
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSCAFG00020026023
Gene Symbol: ERBB3
3 Cross references
280 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSCAFG00020027318
Gene Symbol: ERBB4
3 Cross references
320 Possible Orthologues:

Estrogen Receptor 1

Ensembl ID : ENSCAFG00020014707
Gene Symbol: ESR1
3 Cross references
212 Possible Orthologues:

Estrogen Receptor 2

Ensembl ID : ENSCAFG00020007248
Gene Symbol: ESR2
3 Cross references
274 Possible Orthologues:

Estrogen Related Receptor Gamma

Ensembl ID : ENSCAFG00020004224
Gene Symbol: ESRRG
3 Cross references
206 Possible Orthologues:

Exportin 1

Ensembl ID : ENSCAFG00020026910
Gene Symbol: XPO1
2 Cross references
295 Possible Orthologues:

Farnesyl Diphosphate Synthase

Ensembl ID : ENSCAFG00020006959
Gene Symbol: FDPS
3 Cross references
267 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSCAFG00020011957
Gene Symbol: FDFT1
3 Cross references
218 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).